Health conditions
(Data source: WHO)
Pulmonary embolism/chronic thromboembolic pulmonary hypertension
Circulatory System
Pulmonary embolism
Interventions (Data source: WHO)
Patients with confirmed pulmonary embolism are followed up by regular telephone contacts at 6, 12 and 24 months using a standardised dyspnoea questionnaire. If the questionnaire discovers previously unreported symptoms of dyspnoea, patients are invited to the centre for confirmation of dyspnoea and, if confirmed, an echocardiography will be performed.
In case of a suspicion of PH at echocardiography, right heart catheterisation is performed for the confirmation of PH. CTEPH is confirmed if mean pulmonary arterial pressure (mPAP) greater than or equal to 25 mmHg, pulmonary capillary wedge pressure (PCWP) less than 15 mmHg and pulmonary vascular resistance (PVR) greater than or equal to 300 dyn*sec/cm^5 (3.75 Wood units), and additionally if V/Q scan shows a mismatch or imaging of the lung vessels show a pulmonary vessel obstruction. Any other causes of dyspnoea or elevated PH have to be excluded.
Inclusion/Exclusion Criteria
(Data source: WHO)
Inclusion criteria:
Men and women (no age limitations) with pulmonary embolism within the preceding 4 weeks, demonstrated by:
1. Pulmonary angiography, or
2. Contrast enhanced spiral computed tomography, or
3. High probability lung scintigraphy (perfusion and ventilation imaging)
Exclusion criteria:
1. Confirmed diagnosis of pulmonary arterial hypertension (PAH) or CTEPH before inclusion
2. Pre-existing severe chronic dyspnoea (New York Heart Association [NYHA] grade III or IV) due to other reasons than PE
3. Cancer or other life-threatening disease with a life expectancy less than 6 months
-
Further information on trial
Date trial registered
Jun 29, 2009
Incorporation of the first participant
May 18, 2009
Recruitment status
Completed
Academic title
(Data source: WHO)
Multicentre observational screenINg survey for the detection of chronic thromboembolic PUlmonary hyperTensiON (CTEPH) following Pulmonary Embolism
Type of trial
(Data source: WHO)
Observational
Design of the trial
(Data source: WHO)
Prospective multicentre observational phase V study (Screening)
Phase
(Data source: WHO)
Not Applicable
Primary end point
(Data source: WHO)
Amount of patients who develop symptomatic CTEPH at 6, 12 and 24 months after PE.
Secundary end point
(Data source: WHO)
1. Comparison of collected baseline data of the patients who developed CTEPH with the baseline data of the patients who did not develop CTEPH within the 2-year period after diagnosis of PE to identify any potential risk factors
2. Comparison of the results of the dyspnoea questionnaire answered by telephone with the dyspnoea evaluation by the investigator at the clinic to test the usefulness of the telephone screening algorithm in medical practice for diagnosing CTEPH after PE
Contact information
(Data source: WHO)
Swiss Society for Pulmonary Hypertension (Switzerland)
Trial results
(Data source: WHO)
Results summary
no information available yet
Link to the results in the primary register
no information available yet
Information on the availability of individual participant data
no information available yet
Trial sites
Countries
(Data source: WHO)
Switzerland
Contact for further information on the trial
Contact for scientific information
(Data source: WHO)
John-David
Aubert
University Hospital Lausanne Rue du Bugnon
Further trial identification numbers
Secondary ID (Data source: WHO)
N/A
Back to overview
